Accepted for Publication: September 17, 2021.
Published Online: November 8, 2021. doi:10.1001/jamainternmed.2021.6454
Corresponding Author: Cédric Lemogne, MD, PhD, Service de Psychiatrie de l’adulte, Hôpital Hôtel-Dieu, 1 place du Parvis Notre-Dame, 75004 Paris, France (cedric.lemogne@aphp.fr).
Author Contributions: Drs Matta and Lemogne had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Acquisition, analysis, or interpretation of data: Matta, Wiernik, Robineau, Carrat, Touvier, de Lamballerie, Blanché, Deleuze, Hoertel, Ranque, Goldberg, Lemogne.
Drafting of the manuscript: Matta, Lemogne.
Critical revision of the manuscript for important intellectual content: Matta, Wiernik, Robineau, Carrat, Touvier, Severi, de Lamballerie, Blanché, Deleuze, Gouraud, Hoertel, Ranque, Goldberg, Zins.
Statistical analysis: Matta, Robineau, Hoertel.
Obtained funding: Blanché, Zins.
Administrative, technical, or material support: Blanché, Deleuze, Gouraud, Goldberg, Zins.
Supervision: Carrat, Touvier, Blanché, Gouraud, Goldberg, Lemogne.
Conflict of Interest Disclosures: Dr Robineau reported personal fees and nonfinancial support from Gilead, ViiV Healthcare, and Merck Sharp & Dohme Corp outside the submitted work. Dr Carrat reported personal fees from Sanofi outside the submitted work. Dr de Lamballerie reported grants from the French Ministry of Research and the French Institute of Health and Medical Research during the conduct of the study. Dr Hoertel reported personal fees and nonfinancial support from Lundbeck outside the submitted work. Dr Lemogne reported personal fees from Boehringer Ingelheim, Janssen-Cilag, Lundbeck, and Otsuka Pharmaceutical outside the submitted work. No other disclosures were reported.
Funding/Support: The CONSTANCES cohort benefits from grant ANR-11-INBS-0002 from the French National Research Agency. CONSTANCES is supported by the Caisse Nationale d’Assurance Maladie, the French Ministry of Health, the Ministry of Research, and the Institut National de la Santé et de la Recherche Médicale (INSERM). CONSTANCES is also partly funded by AstraZeneca, Lundbeck, L’Oréal, and Merck Sharp & Dohme Corp. The Santé, Pratiques, Relations et Inégalités Socials en Population Générale Pendant la Crise COVID-19 (SAPRIS) and SAPRIS-Sérologie (SERO) study was supported by grants ANR-10-COHO-06 and ANR-20-COVI-000 from the Agence Nationale de la Recherche; grant 20DMIA014-0 from Santé Publique France; grant 20RR052-00 from the Fondation pour la Recherche Médicale; and grant C20-26 from INSERM.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: A complete list of the members of the SAPRIS-SERO study group appears in Supplement 2.
Additional Contributions: Céline Ribet, PhD, Mireille Pellicer, MD, Laura Quintin, MSc, Stephane Le Got, MSc, all from the CONSTANCES cohort, and Céline Dorival, PhD, and Jerôme Nicol, MSc, from INSERM Institut Pierre Louis d’Epidémiologie et de Santé Publique, substantially contributed to data collection for this work.
1.Nehme
M , Braillard
O , Alcoba
G ,
et al; COVICARE TEAM. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings.
Ann Intern Med. 2021;174(5):723-725. doi:
10.7326/M20-5926
PubMedGoogle ScholarCrossref 9.Carrat
F , Touvier
M , Severi
G ,
et al; SAPRIS study group. Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study.
BMC Infect Dis. 2021;21(1):169. doi:
10.1186/s12879-021-05864-8
PubMedGoogle ScholarCrossref 10.Carrat
F , de Lamballerie
X , Rahib
D ,
et al; SAPRIS and SAPRIS-SERO study groups. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.
Int J Epidemiol.Published online July 19, 2021. doi:
10.1093/ije/dyab110PubMedGoogle Scholar 11.Patel
EU , Bloch
EM , Clarke
W ,
et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers.
J Clin Microbiol. 2021;59(2):e02257-e20. doi:
10.1128/JCM.02257-20
PubMedGoogle ScholarCrossref 12.Morin
AJ , Moullec
G , Maïano
C , Layet
L , Just
JL , Ninot
G . Psychometric properties of the Center for Epidemiologic Studies Depression Scale (CES-D) in French clinical and nonclinical adults.
Rev Epidemiol Sante Publique. 2011;59(5):327-340. doi:
10.1016/j.respe.2011.03.061
PubMedGoogle ScholarCrossref 15.Scherlinger
M , Felten
R , Gallais
F ,
et al. Refining “Long-COVID” by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection.
Infect Dis Ther. 2021;10(3):1747-1763. doi:
10.1007/s40121-021-00484-w
PubMedGoogle ScholarCrossref 17.García-Abellán
J , Padilla
S , Fernández-González
M ,
et al. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study.
J Clin Immunol. 2021;41(7):1490-1501. doi:
10.1007/s10875-021-01083-7
PubMedGoogle ScholarCrossref 18.Datta
SD , Talwar
A , Lee
JT . A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications.
JAMA. 2020;324(22):2251-2252. doi:
10.1001/jama.2020.22717
PubMedGoogle ScholarCrossref 22.Tran
VT , Riveros
C , Clepier
B ,
et al. Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients’ lived experience.
Clin Infect Dis. Published online April 29, 2021. doi:
10.1093/cid/ciab352PubMedGoogle Scholar